Spark Therapeutics, a gene therapy company spun out of Children's Hospital of Philadelphia last year, has entered into a partnership deal worth up to $280 million with Pfizer. The partnership covers the development and potential sale of Spark's experimental hemophilia B treatments.
Under the terms of the agreement, Pfizer (NYSE: PFE) will make an upfront payment of $20 million to Spark. Spark could get up to another $260 million based on reaching undisclosed development and commercialization milestones for its multiple hemophilia B product candidates.
Hemophilia B is rare genetic blood disorder that affects an estimated 4,000 males in the United States and 26,000 males worldwide. The condition is now treated by repeated intravenous infusions.
For more business stories, head to PBJ.com
